IFFIm Newsletter - November 2023

IFFIm earns A+ rating from FCDO

Since 2006, IFFIm has been a critical player in Gavi's financial strategy and its main source of long-term, flexible funding for Gavi 5.0. IFFIm earned an A+ score in the most recent evaluation from the United Kingdom's Foreign, Commonwealth & Development Office (FCDO) "reflecting the continued strong performance of IFFIm over 2021 and 2022 supporting Gavi's implementation."

Here's how the meningitis vaccine works

IFFIm supports Gavi's meningitis programmes with funding of US$ 108 million.

Latest articles

Gavi report highlights rebound in routine immunisation

In its latest Annual Progress Report, Gavi reveals that basic childhood immunisation rebounded in 2022 as lower-income countries collectively contributed US$ 162 million to co-finance Gavi-supported vaccines, the highest amount in their 23-year history.

Read more

IFFIm funding helps #VaccinesWork

Gavi and IFFIm invest in vaccines to fight measles, pneumococcus, rotavirus and yellow fever.

Read more

IFFIm donors gather for annual meeting

At the October gathering, donors expressed support for IFFIm initiatives that extend Gavi's financial strength and help the world prepare for future pandemics.

Read more

Other news

IFFIm rating

October 2023: Moody's affirms IFFIm's Aa1 rating and changes outlook to stable from negative, in line with their change of the UK outlook to stable from negative.

June 2023: Fitch affirms IFFIm at 'AA-'; outlook negative.

Read more